Allarity Therapeutics Inc. (ALLR)
NASDAQ (CM) NASDAQ (CM) Primary 
Allarity Therapeutics, Inc. (ALLR) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates
NEW YORK, NY / ACCESSWIRE / July 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Allarity Therapeutics, Inc. ("Allarity") (NASDAQ:ALLR) concerning possible violations of federal securities laws. Allarity disclosed on July 22, 2024, that it received a Wells Notice from the SEC concerning "the Company's disclosures regarding meetings with the United States Food and Drug Administration (the "FDA") regarding the Company's NDA for Dovitinib or Dovitinib-DRP, which was submitted to the FDA in 2021.
ALLR Investors Have The Opportunity To Join The Allarity Therapeutics, Inc. Securities Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / July 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ:ALLR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Lost Money on Allarity Therapeutics, Inc.(ALLR)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / July 24, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Allarity Therapeutics, Inc. ("Allarity") (NASDAQ:ALLR) concerning possible violations of federal securities laws. Allarity disclosed on July 22, 2024, that it received a Wells Notice from the SEC concerning "the Company's disclosures regarding meetings with the United States Food and Drug Administration (the "FDA") regarding the Company's NDA for Dovitinib or Dovitinib-DRP, which was submitted to the FDA in 2021.
ALLR Stock Alert: Allarity Therapeutics Pushes Shareholders to Back Reverse Split
Allarity Therapeutics (NASDAQ: ALLR ) stock is on the rise Wednesday as the clinical-stage biopharmaceutical company is encouraging its shareholders to vote in favor of a reverse stock split. Allarity Therapeutics put out a press release pushing for investors to approve the reverse stock split during an upcoming shareholder meeting.
